ReviewPhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2026
Insights from a trial of narrowband UVB for early multiple sclerosis.
Review in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a greater prevalence of multiple sclerosis (MS), a neurological autoimmune condition, in populations living further from the equator, hypothesised to be due to reduced sunlight exposure. There exists a proven sunlight surrogate therapy for dermatological inflammatory conditions, in the form of narrowband (NB; 311-312 nm)-UVB phototherapy. Yet, there is a paucity of randomized trials of the therapeutic delivery of NB-UVB beyond dermatology for conditions with a systemic inflammatory component. To investigate the potential for use in MS, the PhoCIS trial (narrowband UVB phototherapy for Clinically Isolated Syndrome)(ACTRN 12614000185662), was established. Participants with Clinically Isolated Syndrome, the earliest symptomatic form of MS, were given NB-UVB (24 sessions over 8 weeks) and followed for 12 months. The published clinical, immunological, and quality of life results from the PhoCIS trial have uncovered new evidence of systemic immune stabilisation by NB-UVB. This perspective provides the first unified overview of these results to inspire future randomised trials of NB-UVB across other autoimmune diseases which share both prevalence that follows UVB exposure, and systemic immune dysregulation.
Indexed as
Identifiers
41886257What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.